### P-aminosalicylate sodium

**Indication**: Multi-drug resistant Mycobacterium tuberculosis

**Medicine type**: Chemical agent

**List type**: Complementary

**Additional notes**: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.

**Formulations**: Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)

**EML status history**: First added in 2023 (TRS 1049)

**Sex**: All

**Age**: Also recommended for children

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**: Patents have expired in most jurisdictions

Read more about patents.

**Wikipedia**: P-aminosalicylate sodium

**DrugBank**: P-aminosalicylate sodium (Aminosalicylic Acid)

### Summary of evidence and Expert Committee recommendations

The Committee recommended deletion from the EML and/or EMLc of various formulations and strengths of amikacin, ethambutol, ethionamide, isoniazid, linezolid, p-aminosalicylic acid and pyrazinamide, noting that they are not optimal formulations and strengths for tuberculosis treatment. A new formulation of p-aminosalicylic acid (as p-aminosalicylate sodium) was recommended for inclusion to replace the previously listed one which has been discontinued by the only manufacturer.